SAN FRANCISCO (January 9, 2017)—ResMed announced today at the 35th annual J.P. Morgan Healthcare Conference that the U.S. Food and Drug Administration has cleared ResMed's AirMini, the world's smallest continuous positive airway pressure (CPAP) device.
ResMed's tiny yet fully-featured AirMini, to be launched later this year, is designed as a secondary CPAP, making it easier for people to continue their sleep apnea therapy while traveling.
As an addition to ResMed's industry-leading Air Solutions portfolio, the AirMini offers multiple benefits to home medical equipment providers—supporting increased therapy compliance and convenience for their patients, and incremental revenue opportunities.
"ResMed AirMini is the portable travel CPAP patients and home medical equipment providers have been waiting for, and we look forward to bringing it to market later this year," said ResMed CEO, Mick Farrell. "It fits easily in carry-on luggage—even in the seatback pocket on the plane–and delivers all the best-in-class comfort features patients need to get the best sleep."
Visit resmed.com for more information.
